Improving insulin resistance with metformin, a medication used to treat type 2 diabetes, reduced the chances of developing kidney disease in a prepubescent obese rat model, according to a new study from the University of Mississippi Medical Center. Treatment with metformin also reduced early signs of inflammation and dyslipidemia (imbalance of fats such as cholesterol and triglycerides).
Metformin cuts insulin resistance and chances of kidney disease in young, obese rats
Improving insulin resistance with metformin, a medication used to treat type 2 diabetes, reduced the chances of developing kidney disease in a prepubescent obese rat model, according to a new study from the University of Mississippi Medical Center. Treatment with metformin also reduced early signs of inflammation and dyslipidemia (imbalance of fats such as cholesterol and triglycerides).